Next-Generation Sequencing of

AML DDX41 MDS germline hereditary

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 10 07 2020
accepted: 02 11 2020
entrez: 15 2 2021
pubmed: 16 2 2021
medline: 16 2 2021
Statut: epublish

Résumé

Previously considered rare, inherited hematologic malignancies are increasingly identified. Germline mutations in the RNA helicase

Identifiants

pubmed: 33585199
doi: 10.3389/fonc.2020.582213
pmc: PMC7878971
doi:

Types de publication

Journal Article

Langues

eng

Pagination

582213

Subventions

Organisme : NCI NIH HHS
ID : R01 CA255721
Pays : United States

Informations de copyright

Copyright © 2021 Bannon, Routbort, Montalban-Bravo, Mehta, Jelloul, Takahashi, Daver, Oran, Pemmaraju, Borthakur, Naqvi, Issa, Sasaki, Alvarado, Kadia, Konopleva, Shamanna, Khoury, Ravandi, Champlin, Kantarjian, Bhalla, Garcia-Manero, Patel and DiNardo.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer CH declared a past co-authorship with one of the authors CD to the handling editor.

Références

Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):417-428.e2
pubmed: 27210295
Int J Hematol. 2017 Aug;106(2):163-174
pubmed: 28547672
Leuk Lymphoma. 2013 Jan;54(1):28-35
pubmed: 22691122
Blood. 2015 Nov 26;126(22):2484-90
pubmed: 26492932
Leukemia. 2017 May;31(5):1226-1229
pubmed: 28104920
Blood. 2016 Feb 25;127(8):1017-23
pubmed: 26712909
Cancer. 2018 Jul 1;124(13):2704-2713
pubmed: 29682723
Nat Immunol. 2011 Sep 04;12(10):959-65
pubmed: 21892174
Leukemia. 2017 Apr;31(4):1020-1022
pubmed: 28194039
Cancer Cell. 2015 May 11;27(5):658-70
pubmed: 25920683
Am J Hematol. 2020 Feb;95(2):227-229
pubmed: 31400013
Leukemia. 2017 Feb;31(2):520-522
pubmed: 27795557
Blood. 2019 Oct 24;134(17):1441-1444
pubmed: 31484648
Best Pract Res Clin Haematol. 2015 Mar;28(1):55-68
pubmed: 25659730
Semin Hematol. 2017 Apr;54(2):94-97
pubmed: 28637623
Leuk Lymphoma. 2016;57(3):520-36
pubmed: 26693794
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Am J Hematol. 2019 Jul;94(7):757-766
pubmed: 30963592
Blood Adv. 2018 Jan 23;2(2):146-150
pubmed: 29365323

Auteurs

Sarah A Bannon (SA)

Department of Clinical Cancer Genetics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Mark J Routbort (MJ)

Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Guillermo Montalban-Bravo (G)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Rohtesh S Mehta (RS)

Department of Stem Cell Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Fatima Zahra Jelloul (FZ)

Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Koichi Takahashi (K)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Naval Daver (N)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Betul Oran (B)

Department of Stem Cell Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Naveen Pemmaraju (N)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Gautam Borthakur (G)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Kiran Naqvi (K)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Ghayas Issa (G)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Koji Sasaki (K)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Yesid Alvarado (Y)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Tapan M Kadia (TM)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Marina Konopleva (M)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Rashmi Kanagal Shamanna (RK)

Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Joseph D Khoury (JD)

Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Farhad Ravandi (F)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Richard Champlin (R)

Department of Stem Cell Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Hagop M Kantarjian (HM)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Kapil Bhalla (K)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Guillermo Garcia-Manero (G)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Keyur P Patel (KP)

Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Courtney D DiNardo (CD)

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Classifications MeSH